Trevi Corp - TRVI Total Company Value
Trevi Therapeutics (TRVI) specializes in developing therapeutic agents to combat chronic cough. This price chart reflects an Enterprise Value of 1649.32, while the company lacks stable revenue and relies on external funding. High scalability potential is ensured by outsourcing production to contractors following IP registration. In the future, patents will enable the company to establish premium pricing.
Trevi Therapeutics - analytical breakdowns and key metrics (TRVI)
- stock quotes and analyst forecast:
- issuer market value details:
- business book valuation details:
- business debt structure and liquidity details:
Debt to Capital Trevi Therapeutics|TRVI - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital trevitherapeutics.com|TRVI - Company Debts|Debt to Net Assets Ratio Trevi Therapeutics|TRVI - Company Long-Term Debt|Short-Term Debt Trevi Therapeutics|Intermediate Liquidity Ratio trevitherapeutics.com
- company profitability and valuation multiples indicators:
Analysis of all company metrics:Trevi Therapeutics Inc
Enterprise Value determines the total buyout cost of a business by combining market capitalization with net debt. By analyzing the indicative Enterprise Value level, an investor sees the real price of the asset net of liquid assets. This metric is sensitive to debt load and cash volume. For Trevi Therapeutics (TRVI), this figure reflects the value of the infrastructure, including scalable capacities for the production of neuro-drugs. The valuation confirms the investment attractiveness of the company's production potential.
Competitors of Trevi Therapeutics (TRVI)
Value Adjusted for Debt and Cash BIIB|NBIX: Real Price to Acquire Entire Company|RGC: Total Company Value|AXSM: Enterprise Value|ACAD - Company Buyout Price|Total Company Value Xenon|Business Value VKTX (Viking Therapeutics Inc)|Enterprise Value SUPN|CPRX - Total Enterprise Value|Denali Therapeutics - Real Price to Acquire Entire Company|Enterprise Value harmonybiosciences.com HRMY|BHVN - Total Company Value|Value Adjusted for Debt and Cash AMLX (Amylyx Pharmaceuticals Inc)|Praxis Medicines (PRAX) - Total Company Value|Total Enterprise Value Anavex Life Sciences Corp (AVXL)|Real Price to Acquire Entire Company CBLL|PRTA (Prothena Corp) - Aggregate Business Value|Total Company Value Alector, Inc. (ALEC)|ANNX (Annexon Biosciences) - Value Adjusted for Debt and Cash|Enterprise Value OMER (Omeros)|Neurogene Therapeutics (NGNE) - Total Enterprise Value|ACIU: Real Price to Acquire Entire Company|VYGR: Total Company Value|NMRA: Enterprise Value|SCLX - Company Buyout Price|Real Price to Acquire Entire Company TVGN|ACOG: Value Adjusted for Debt and Cash|Real Price to Acquire Entire Company CGTX (Cognition Therapeutics, Inc.)|Aggregate Business Value IKT|Enterprise Value SAVA (Cassava Sciences)|Value Adjusted for Debt and Cash ASRT|Coya - Enterprise Value|Total Enterprise Value Vistagen Therapeutics|ovidrx.com (OVID) - Total Company Value|acumenpharm.com - Value Adjusted for Debt and Cash|CRVO (CervoMed) - Enterprise Value|Enterprise Value Alterity Therapeutics Ltd|Total Company Value Clene Inc. (CLNN)|PEPG: Full Business Value|Enterprise Value JUNS (Jupiter Neurosciences)|relmada.com (RLMD) - Total Enterprise Value|ANVS: Real Price to Acquire Entire Company|GRCE - Enterprise Value|AIFF (Firefly Neuroscience Inc) - Real Price to Acquire Entire Company|KLTO: Aggregate Business Value|NRSN (NeuroSense Therapeutics Ltd) - Enterprise Value|revivapharma.com (RVPH) - Company Buyout Price|Enterprise Value MTVA|Real Price to Acquire Entire Company NeurAxis Inc. NRXS|Total Company Value Helius Medical Technologies HSDT|Company Buyout Price Passage Bio Inc. (PASG)|NEUP: Real Price to Acquire Entire Company|minervaneurosciences.com - Aggregate Business Value|Athira Pharma (ATHA) - Total Company Value|Addex Therapeutics Ltd. - Value Adjusted for Debt and Cash|Real Price to Acquire Entire Company ALZN|Total Company Value CYCN|Enterprise Value PTIX|Company Buyout Price pasitheaclinics.com|Total Company Value Cortigent CRGT|ATXI: Business Value|Brainstorm Cell Therapeutics, Inc. - Enterprise Value|Total Enterprise Value Cara Therapeutics Inc|CHRO (Chromocell Therapeutics) - Real Price to Acquire Entire Company|Eliem Therapeutics Inc. (ELYM) - Enterprise Value|Total Company Value Intra-Cellular Therapies Inc.|LBPH: Value Adjusted for Debt and Cash|Total Company Value Marinus (MRNS)|NKGN - Total Enterprise Value|NeuroBo Pharmaceuticals - Real Price to Acquire Entire Company|Aggregate Business Value SAGE (sagerx.com)|SNPX - Total Company Value|Value Adjusted for Debt and Cash TRVN (Trevena Inc.)|VIGL: Enterprise Value|Total Enterprise Value anewmeds.com (WENA)|Real Price to Acquire Entire Company CERE